Background: Children with high-risk medulloblastoma historically have had a poor prognosis. The Children's Oncology Group completed a Phase II study using oral etoposide given with radiotherapy followed by intensive chemotherapy.
INTRODUCTION
Central nervous system (CNS) tumors as a group make up the most common solid tumors in children. Of these, medulloblastoma is the most common malignant tumor and comprises 9.3% of CNS tumors in the 0-14-year-old age group and has an incidence rate of 0.49 per 100,000. 1 Therapy for high-risk medulloblastoma has improved over time from the early 1970s when the 5-year survival was around 40% to now being over 60%. 1 The standard of care at Children's Oncology Group (COG) institutions for the treatment of high-risk medulloblastoma in those >3 years of age has usually been and is still craniospinal radiation (CSRT) with concurrent chemotherapy followed by maintenance chemotherapy. [2] [3] [4] [5] [6] The Pediatric Oncology Group (POG) previously showed in the 9031 study that the use of chemotherapy either before or after CSRT was effective in treating high-risk medulloblastoma, with the 5-year progression-free survival (PFS) of 68.1% and overall survival (OS) of 74.6%. 6 POG 9631 was undertaken to evaluate if giving oral etoposide during radiation in combination with post-CSRT adjuvant chemotherapy could improve survival. Oral etoposide previously has been used successfully in the treatment of recurrent medulloblastoma, but this is the first study to use upfront oral etoposide during radiation in newly diagnosed high-risk medulloblastoma patients. [7] [8] [9] [10] 
MATERIALS AND METHODS

Patient population
Patients were between the age of 3 and 21, with high-risk medulloblastoma as defined by one of the following: residual disease of ≥1.5 cm 2 on postoperative computed tomography or magnetic resonance imaging performed both with and without contrast, preferably within 72 hr of surgery, or between day 10 and 21 after surgery; definite evidence of CNS metastases at diagnosis (M 1 -M 3 by Chang classification) or presence of extraneural metastasis confirmed histologically (M 4 ). 11 Patients had to have no previous radiotherapy or chemotherapy other than corticosteroids. Other eligibility criteria included adequate physiologic functions defined as absolute neutrophil count ≥1,500 per l -1 , platelets ≥100,000 l -1 , serum creatinine <1.7 mg/dl or creatinine clearance >70 ml/min/1.73 m 2 , serum glutamic pyruvic transaminase less than five times normal, and bilirubin less than 1.5 mg/dl. Informed consent was obtained as per institutional guidelines and patients began therapy within 1 month of definitive surgery. Pregnant and breast-feeding women were not eligible for this study. Radiology was centrally reviewed by the principal investigator, the study neuroradiologist, and the study radiation oncologist. Pathology was reviewed centrally; however, specific histologic data for each tumor is no longer available. The study was approved by an institutional review board at each participating site and all subjects or their parents signed informed consent.
Study design
The treatment schema for POG 9631 is given in Supplementary   Figure S1 . All the patients underwent surgical debulking followed by CSRT with boost to the posterior fossa. Sites of metastatic disease were given an additional radiation therapy boost of 5.4 Gy. During CSRT, the patients received daily oral etoposide on days 1-21 and 29-49 dosed at 50 mg/m 2 per day (treatment 1). After 12 patients, there was a stopping rule to allow assessment of toxicity, and the dose of etoposide was decreased to 35 mg/m 2 per day for subsequent patients (treatment 2) due to two episodes of grade IV dysphagia. Three additional patients were already enrolled before the change was made, so a total of 15 patients were assigned to receive treatment 1. Four weeks after the completion of chemoradiotherapy, the patients received three courses of monthly intravenous cisplatin 90 mg/m 2 per day given with oral etoposide on days 1 through 21 (same dose as given during radiation), followed by eight monthly cycles of intravenous cyclophosphamide 1.5 g/m 2 per day for 2 days and weekly intravenous vincristine 1.5 mg/m 2 (days 1, 8, and 15). Granulocyte stimulating factor was administered at 5 g/kg per day for at least 10 days starting 24 hr after the last chemotherapy. 
Radiation
STATISTICAL ANALYSIS
The original objectives of the study were to (1) estimate response rate and describe toxicities; (2) compare response rate and toxicity to historical control patients treated on POG 9031 treatment 2 (radiation therapy followed by adjuvant chemotherapy) who would have been eligible for treatment on POG 9631; (3) estimate 2-year PFS and OS rates; and (4) evaluate toxicity of adjuvant chemotherapy. Comparisons between groups were compared using Fisher exact test. PFS was calculated from the on-study date to the date of disease progression or date of death, and OS to the date of death. Patients who did not experience an event for PFS or OS were censored at their last followup date. The survival distributions were estimated using the KaplanMeier method and compared with POG 9631 and POG 9031 using the log-rank test. The association of age at diagnosis with PFS and OS was investigated using a Cox proportional hazards model. The study was powered to detect 20% improvement in the historical POG 9031 objective response rate of 69%.
Response was assessed at the end radiation and again at the end 
RESULTS
The baseline data for the cohort by treatment group are given in Table 1 . Between November 1998 and October 2002, a total of 53 patients with newly diagnosed medulloblastoma were accrued. Six patients were declared ineligible (two did not meet criteria for highrisk disease, one did not meet inclusion criteria, and three did not follow guidelines related to timing for start of therapy). This resulted in 47 eligible subjects. Thirteen received treatment 1 and 34 treatment 2. The median age of patients was 8.1 years (range 3.2-21.2). The cohort was 72% male and 91% Caucasian. The M stages were M 0 with >1.5 cm 2 residual n = 12, M 1 n = 11, M 2 n = 6, M 3a n = 6, M 3b n = 12, and M 4 n = 0.
Response to radiation and at end of therapy
The response to therapy according to the treatment group and stage are given in Table 2 . All patients with reported data regardless of therapy showed at least a PR to radiation. After radiation, there was no difference in the response to therapy between the two etoposide treatments, but there was a significant difference in CR between those with M 0 , M 1 , or M 2 disease compared with those with M 3 disease (P = 0.013). The response at the end of therapy was also not different between etoposide treatment groups, but again the number of subjects with CR was higher in those with M 0 , M 1 , or M 2 disease compared with those with M 3 disease (P = 0.002). Progression by the end of therapy was higher in etoposide group 2 (14.7%) than in group 1 (7.7%); however, this did not reach statistical significance.
Survival
The event-free and OS information is given in Table 2 . The 2-and 5-year PFS for the entire study was 76.65 ± 6 and 70.2 ± 7%, respectively. The 2-and 5 year OS was a little better at 80.9 ± 6 and 76.6 ± 6%, respectively. The 2-and 5-year PFS/OS did not differ between etoposide treatment groups (Fig. 1 ). There was a trend toward a difference in 5-year PFS/OS between those without and with metastatic disease (P = 0.072 for PFS and P = 0.096 for OS) (Fig. 2 ).
Comparison to POG 9031
Response and survival outcomes were compared to patients treated with POG 9031. 6 In POG 9031, there were 112 patients, 57 of whom were evaluable for response and 73 were evaluable for survival.
Twenty-six patients were excluded from the comparison because of 
Toxicities
Toxicities were as expected and mainly hematologic (Table 3) , and cumulative toxicities are given in Supplementary Table S1 . During radiation, anemia and neutropenia were more common in etoposide group 1, 3/13 (23%), and 8/13 (62%), respectively, versus in etoposide group 2, 1/47 (3%), and 10/47 (29%); however, there was no difference in the need for transfusions. In etoposide group 1, there was a high incidence of dysphagia and esophagitis related to radiation 4/15 (26.7%), leading to a decrease in the etoposide dose. In etoposide group 2, dysphagia was seen less often 2/34 (5.9%). There was no difference in other gastrointestinal and renal toxicities between etoposide groups, and grade 3 or 4 toxicities occurred sporadically with anorexia, with nausea/vomiting being most common. Infections were rare during radiation and common during the more intensive parts of chemotherapy (Table 3 ). Other serious toxicities that occurred rarely included hemorrhage in two, pericardial effusion in one, syndrome of inappropriate antidiuretic hormone secretion in one, ataxia in four, alternated consciousness in two, and vision changes in one. There have been 13 deaths at the time of censoring, March 2007; four were on treatment 1 and nine on treatment 2. One death was due to hemorrhage, one to radiation-induced vasculopathy, and one to multi-organ failure during bone marrow transplant. All other deaths were due to tumor progression.
DISCUSSION
High-risk medulloblastoma remains a challenging disease to treat, but this study was able to achieve good 5-year PFS (70%) and OS (77%) similar to or superior to other contemporary high-risk medulloblastoma trials, with PFS ranging from 43 to 71% and OS from 52 to 82%. [2] [3] [4] [5] [6] 12, 13 In this trial and others, the inclusion of CSRT and intensive chemotherapy has improved PFS. Specifically, it showed similar results to the POG 9031 arm that also gave chemotherapy postradiation. 6 This is a first pediatric brain tumor study to use oral etoposide during radiation. Oral etoposide was selected based on the experience with relapsed medulloblastoma. 7, 8 Chamberlain et al. 8 showed that in one adult and seven pediatric patients with relapsed medulloblastoma who received oral etoposide, five out of eight (63%) had either PR or SD that was sustained for a period ranging from 4 to 10 months. Ashley et al. 7 showed in a similar population of pediatric relapsed medulloblastoma subjects, with six of seven subjects who received oral etoposide monotherapy having a PR and the remaining patient having SD. In this study, giving oral etoposide during radiation resulted in excellent response rates during radiotherapy, with over 40% of the subjects showing a CR and all subjects who have reported data showing at least a PR. Subjects receiving the higher dose of etoposide (50 mg/m 2 per dose) had a high rate of dysphagia/esophagitis 26.7%, which was considered a dose-limiting toxicity; however, this was much rarer (5.9%) in the lower dose etoposide group (35 mg/m 2 per dose) and there were no other significant dose-limiting toxicities in either group during radiation. Thus, use of oral etoposide during radiation, though feasible and tolerable, would need to be evaluated in a larger trial to assess for toxicity before it is accepted as the standard of care. COG as well as HIT-SIOP has evaluated other therapies during radiation and the standard of care has been to give vincristine weekly during radiation and has had a low complication rate (<5% rate peripheral neuropathy/ileus). 4,14 Jakacki et al. 4 published the results from a Phase I/II COG study for high-risk medulloblastoma that in the superior arm added carboplatin to vincristine during radiation followed by maintenance cyclophosphamide and vincristine, which showed nearly the same long-term PFS (71%) /OS (82%) as this study. Radiationinduced esophagitis was also seen in this study on the carboplatin arm as well, though in only 3.8% of the subjects; however, 14.6% of the subjects hit some type of dose-limiting toxicity during radiation and there was a high prevalence of ototoxicity. 4 This strategy of adding carboplatin during radiation for high-risk medulloblastoma is being evaluated as a randomized question in a current COG study (ACNS 0332). Another agent that has been shown to be safe to give during radiation in adults is temozolomide and there is pediatric data that have shown it is active against medulloblastoma; however, published pediatric toxicity data for this approach are still lacking. [15] [16] [17] This study was not powered to assess the difference in survival between those with M 0 with residual disease and those with more extensive metastatic disease; however, there was a trend toward higher survival in those with M 0 disease with residual over those with more extensive disease. This survival difference was confirmed in the larger POG 9031 trial. 6 This study is limited by not having specific histologic or molecular stratification of tumors. The presence of anaplasia has been shown to be a negative prognostic features in several studies, 3, 4 and more recently medulloblastoma has been molecular stratified into groups that also impact survival. [18] [19] [20] This new molecular information at this point is useful for prognostic information, but there is great potential that using it will lead to more specifically targeted drug therapy and so should be considered anytime new medulloblastoma studies are designed. It is an interesting finding that being older at diagnosis was associated with better PFS and OS even when adjusted for M staging. The reason for this finding is not clear, as subjects were given the same chemotherapy/radiation plan regardless of age. Unfortunately, this study is too small to investigate if other factors could have contributed to this finding.
TA B L E 1 Characteristics of the cohort by treatment group
TA B L E 2 Response to therapy
In conclusion, this study showed that the approach of using oral etoposide with CSRT followed by intensive chemotherapy is feasible and results in good PFS and OS that is similar to other high-risk regimens and had minimal toxicity at the lower etoposide dose. Thus, it may be a reasonable treatment regimen to consider in future trials for newly diagnosed high-risk medulloblastoma patients. Future molecular stratified studies will be necessary to discover for which medulloblastomas this treatment would be most effective.
